SCHEMBL7053774

SCHEMBL7053774

CCCCc1ncc(CC(=O)N[C@@H](Cc2ccccc2)C(=O)O)n1Cc1ccccc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9473033 1.00 — —
SCHEMBL8971903 0.93 — —
SCHEMBL8971896 0.93 — —
SCHEMBL9473261 0.92 — —
SCHEMBL9475007 0.92 — —
SCHEMBL9473826 0.92 — —
SCHEMBL8971489 0.89 — —
SCHEMBL8957067 0.88 — —
SCHEMBL8957070 0.88 — —
SCHEMBL7049832 0.88 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5234917-A Hypotensive agent, treatment of renal failure or glaucoma SMITHKLINE BEECHAM CORPORATION 1993-08-10 — — US claimed
EP-0437103-A2 Substituted 5-(alkyl)carboxamide imidazoles SMITHKLINE BEECHAM CORPORATION (US) 1991-07-17 — — EP claimed
US-20030187044-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-10-02 — — US disclosed
US-20030166700-A1 Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression SMITHKLINE BEECHAM P.L.C. 2003-09-04 — — US disclosed
US-20030096851-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-05-22 — — US disclosed
EP-0724387-B1 ANGIOTENSION II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES SMITHKLINE BEECHAM CORP (US) 2003-05-02 — — EP disclosed
US-20030069293-A1 Medicament SMITHKLINE BEECHAM PLC 2003-04-10 — — US disclosed
US-20030050285-A1 Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke SMITHKLINE BEECHAM P.L.C. 2003-03-13 — — US disclosed
US-20030004201-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-01-02 — — US disclosed
US-20020160985-A1 Medicament SMITHKLINE BEECHAM PLC 2002-10-31 — — US disclosed
US-20020132840-A1 Treating angina in a mammal by administering an angiotensin II receptor antagonist. SMITHKLINE BEECHAM P.1.C. 2002-09-19 — — US disclosed
US-5234917-A Hypotensive agent, treatment of renal failure or glaucoma SMITHKLINE BEECHAM CORPORATION 1993-08-10 — — US disclosed
WO-1993006828-A1 MEDICAMENT FOR THE TREATMENT OF ANXIETY SMITHKLINE BEECHAM CORPORATION (US) 1993-04-15 — — WO disclosed
WO-1992010184-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF ATHEROMA SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010185-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010097-A1 ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS SMITHKLINE BEECHAM CORPORATION (US) 1992-06-25 — — WO disclosed
WO-1992010181-A1 USE OF ANGIOTENSIN II ANTAGONISTS IN THE TREATMENT OF LEFT VENTRICULAR HYPERTROPHY SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010187-A1 USE OF ANGIOTENSIN II ANTAGONISTS IN THE TREATMENT OF ANGINA PECTORIS SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010180-A1 USE OF ANGIOTENSIN II ANTAGONIST IN THE TREATMENT OF INFARCTION SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
EP-0437103-A2 Substituted 5-(alkyl)carboxamide imidazoles SMITHKLINE BEECHAM CORPORATION (US) 1991-07-17 — — EP disclosed
Send feedback